Key facts
- Prediction markets are now offering wagers on drug approvals and clinical trial outcomes.
- Kalshi is launching a pilot program in partnership with AppliedXL to facilitate these bets.
- Critics warn of increased risks of insider trading, data leaks, and market manipulation.
- Kalshi plans to implement safeguards such as employment verification and listing contracts post-trial enrollment.
- Supporters argue these markets can increase transparency in the often opaque drug development process.
Prediction market platforms like Kalshi and Polymarket are expanding their offerings to include wagers on the outcomes of drug clinical trials and regulatory approvals, a move that has ignited debate about the intersection of finance and healthcare.
Kalshi, in partnership with AI firm AppliedXL, is launching a pilot program to allow bets on drug trial results and FDA regulatory decisions. The company states this initiative aims to increase transparency in the drug development industry, which is often characterized by information constraints and opaque data.
However, critics have raised significant concerns regarding the potential for market manipulation, illegal insider trading, and the ethical implications of financializing life-saving medical research. The involvement of individuals with access to non-public trial data poses a substantial risk, as demonstrated by past instances of insider trading on other prediction platforms. The Department of Justice is also investigating former congressman George Santos for alleged insider trading related to his attendance at the State of the Union address, and Donald Trump's former teleprompter operator reportedly made significant profits from bets on presidential speeches.
Kalshi has stated that it will implement safeguards, including employment verification to prevent insider trading and will only list contracts after drug trial enrollment has closed to avoid influencing recruitment. Anne Wojcicki, founder of 23andMe, has expressed support for the concept, viewing it as a promising way to create a more transparent dataset for clinical trial probabilities.
In addition to drug trials, Kalshi is also planning to offer contracts for betting on flight cancellations, a move that has drawn a statement from FlightAware, which asserts that its data is not authorized for use in prediction markets.